Browsing by Author "MEHMET ALI ERKURT"

Now showing 1 - 1 of 1
  • No Thumbnail Available
    Item
    A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera
    (2023) Fevzi Altuntaş; Mustafa Merter; MEHMET ALI ERKURT; ISMET AYDOGDU; MURAT ALBAYRAK; Sibel Hacioglu; Mehmet Hilmi Doğu; ABDULKADIR BASTURK; Omer Ekinci; Fadime Ersoy Dursun; SİNAN DEMİRCİOĞLU; ANIL TOMBAK; Istemi SERIN; Gulsum Akgun Cagliyan; MERİH REİS ARAS; Burhan Turgut; METIN BAGCI; Serdal Korkmaz; MEHMET SİNAN DAL; Turgay Ulas
    Introduction: Ruxolitinib is a small -molecule inhibitor of the JAK1/2 pathway. This study aimed to reveal the results and side-effect profile of the use of ruxolitinib as a treatment option in polycythemia vera (PV). Methods: A total of 34 patients with PV from 18 different centers were included in the study. The evaluation of the response under treatment with ruxolitinib was determined as a reduction in spleen volume (splenomegaly size: ≥35%) by imaging and control of hematocrit levels (≤45%) compared to baseline. Results: While the number of patients in which a reduction in spleen volume and hematocrit control was achieved was 19 (55.9%) at 3 months of treatment, it was 21 (61.8%) at 6 months. Additionally, while the number of side effects was negatively correlated with the reduction in spleen volume (Spearman’s rho: -0.365, p=0.034), a decrease in the hematocrit level was positively correlated (Spearman’s rho: 0.75, p=0.029). Those without a reduction in spleen volume experienced more constipation (chi-square: 5.988, Fisher’s exact test: p=0.033). Conclusion: This study shed light on the use of ruxolitinib in PV and the importance of splenomegaly on studies planned with larger patient groups.